A Phase 2, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Therapy and Combinations in Patients with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

August 07, 2018
Gastroenterology Hepatology
Principal Investigator: Kimberly A Brown, MD
NASH, nash, nonalcoholic steatohepatitis, fibrosis, f3, f4, cirrhosis, compensated cirrhosis,